Financial Performance - The company reported a 15.91% decrease in revenue from distributors, accounting for 28.62% of total revenue, down from 33.56% in the same period last year [6] - Direct sales revenue increased by 6.68%, representing 14.60% of total revenue, compared to 13.49% last year [6] - Revenue from controlled terminals grew by 5.70%, making up 56.78% of total revenue, up from 52.95% last year [6] Product Promotion and Market Trends - The new DK185 corneal shaping lens has seen a user acceptance rate with a market share increase from 0.6% in June to 7% currently [2] - The scleral lens, launched in March, currently holds a market share of approximately 0.6% [2] - The company is focusing on promoting the scleral lens to adults, particularly those with dry eyes, indicating significant market potential [2] Strategic Developments - The company added 30 optical terminals in the first half of 2025, bringing the total to over 520, while hospital partnerships increased to about 30 [2] - The company is cautious about new optical terminal investments, prioritizing those with substantial feasibility and growth potential [2] Industry Dynamics - The trend of separating product and service pricing in public hospitals is influencing overall product pricing, leading to a general decrease [3][4] - The company has introduced affordable products in response to market demands, aiming to make corneal shaping lenses accessible to more families [4] Research and Development - The company has multiple products in development, including advanced corneal and scleral lenses, cleaning solutions, and new medical devices expected to launch within 1-3 years [5] - The AAV research by the invested ophthalmic innovation company, Xingmou, has entered phase II clinical trials [5] E-commerce Growth - E-commerce sales, primarily for care products, are experiencing rapid growth, with plans to expand product offerings and improve online sales channels [6]
欧普康视(300595) - 2025年8月25日投资者关系活动记录表